Sorin Universal REgistry on Aortic Valve Replacement



Status:Recruiting
Conditions:Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:8/15/2018
Start Date:May 2015
End Date:May 2029
Contact:Gaia Giannicola
Email:gaia.giannicola@livanova.com
Phone:+393451174649

Use our guide to learn which trials are right for you!

Multi-center, International, Prospective, Non comparative, Non randomized, Open label.

5,000 patients to be enrolled approximately worldwide.

The objective of this registry is to collect safety and clinical performance post market data
related to the procedure and follow-up of the Sorin Group aortic valve devices in accordance
with the Instructions for Use (IFU).

This observational global registry is intended to collect data without requiring any
deviation from the standard of care and IFU in each participating center. The participating
centers shall include those patients that have provided their informed consent to participate
in this registry in accordance with the local applicable regulations.

SURE-AVR objective is to collect post market safety and performance data collected along the
procedure and the relevant follow-up with Sorin Group aortic valve devices in accordance with
the IFU to further evidence the safety and efficacy in a post-approval environment. All
current and future Sorin Group aortic valve devices that have obtained CE-mark or other local
regulatory and/or commercial approvals may be included in the registry. During the duration
of the registry,other aortic valve replacement products or current devices might receive
modifications and might become commercial available. This registry allows extensions for the
inclusion of new products.

This observational global registry is intended to collect data without requiring any
deviation from the standard of care and IFU in each participating center. The participating
centers shall include those patients that have provided their informed consent to participate
in this registry following the local applicable regulations.

The data collection shall be performed as per the local standard of care and without exposing
the patient to any additional risk to the treatment (s)he would normally receive.

The registry is an open-ended project:

- Inclusions phase: open-ended

- Follow-up phase: annually throughout 5 years (7 and 10 years are optional).

The study shall be completed after the 10-year follow-up of the last patient.

Inclusion Criteria:

- All patients must provide written or oral informed consent to participate in the
registry depending on the local regulations.

- Patients having received a Sorin Group aortic valve device in accordance with the IFU

Exclusion Criteria: NA
We found this trial at
6
sites
701 Princeton Avenue Southwest
Birmingham, Alabama 35211
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Columbus, Ohio 43213
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Jacksonville, Florida 32207
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
?
mi
from
Melbourne,
Click here to add this to my saved trials
New York, New York 10032
?
mi
from
New York, NY
Click here to add this to my saved trials
4700 Alliance Boulevard
Plano, Texas 75093
?
mi
from
Plano, TX
Click here to add this to my saved trials